PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
June 26, 2026Neuro-Oncology Pediatrics

ID #992 Trajectory-Aware Functional Drug Screening Bridges Preclinical and Clinical Response Metrics in Diffuse Midline Glioma

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAna Castro MarquezBKBettina KritzerSLSandra Laternser

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates improved drug response metrics in diffuse midline glioma, supporting treatment optimization.

Key Points

  • This research aims to bridge the gap between preclinical drug screening and clinical response assessment for diffuse midline glioma.
  • Tested 33 therapeutics across three concentrations in 10 patient-derived DMG spheroids over two weeks.
  • Utilized an automated live-cell imaging platform for dynamic response quantification.
  • Analyzed response profiles with an ordinary differential equation framework and clustered inferred parameter distributions.
  • Achieved high R2 values indicating excellent fits: Rcell_line2 = 0.969 and Rcompound2 = 0.97.
  • Identified response dynamics clusters aligned with drug mechanisms, revealing distinct treatment effects.
  • Strong concordance between mechanistic clusters and trajectory-based clustering, enhancing translational relevance.

Cite This Study

Marquez et al. (2026) studied this question.

synapsesocial.com/papers/6a3e1995030ad1a9b3092386https://doi.org/10.1093/neuped/wuag026.434
View Full Paper
Ask AI
Bookmark
Share